KLOW blend (BPC-157 + TB-500 + GHK-Cu + KPV)

Skin & Cosmetic · listed as KLOW

No controlled study, in humans or animals, has evaluated the four-way combination of BPC-157, the TB-500 fragment, GHK-Cu and KPV. The only combination data located is a 2026 rat Achilles-tendon study of BPC-157 plus TB-500 alone, in which the pair did not outperform either peptide individually. KPV has no human exposure data at all (FDA statement), and the other components have no completed human randomised trials for the marketed forms. Evidence for each component is summarised in its own entry; FDA Category 2 safety statements exist for all four components.

No combined trials1 reported adverse effect0 documented interactions4 references

🔬 Research use only — not for human or veterinary use. The regimens below are records of what published studies administered to their own subjects; they are not instructions and K4 Elite does not provide dosing instructions.

Published trial usage Adverse effects Interactions Contraindications References

Published trial usage

No controlled studies of this combination exist

No randomised, controlled or otherwise comparative study of this multi-component preparation as a combination has been published, in humans or in animals. There is therefore no trial regimen, no combined safety dataset and no interaction dataset to report for the blend itself.

What has been published concerns the individual components, each of which has its own record:

BPC-157Preclinical only TB-500 (Thymosin beta-4 fragment, Ac-LKKTETQ)Preclinical only GHK-Cu (glycyl-L-histidyl-L-lysine copper complex)Human (small/observational)KPV (Lys-Pro-Val; α-MSH 11-13)Preclinical only

Reported adverse effects

Effects recorded in the cited reports. Frequencies are those the source reported, in the population that source studied.

Effect	Frequency / context	Source
No adverse-event data exist for the combination	No trial of the four-component blend has been conducted. FDA states it has no human exposure data for KPV or for the thymosin beta-4 fragment, and only limited human data for BPC-157 and injectable GHK-Cu.	FDA — Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks ↗

Interactions

No interactions with a verifiable citation have been indexed for this compound.

Contraindications noted in trials

Exclusions and label contraindications recorded in the cited sources.

None established for the combination. FDA Category 2 statements cover BPC-157, the thymosin beta-4 fragment (TB-500), injectable GHK-Cu and KPV individually, citing immunogenicity/impurity risk and limited or absent human safety data. Source ↗

References

Elsewhere on K4 Elite

KLOW Blend (BPC-157 · TB-500 · GHK-Cu · KPV) — product page KLOW Blend (BPC-157 · TB-500 · GHK-Cu · KPV) — Peptide Research Library All indexed compounds — Research Trials

Research use only. This record summarises published literature for reference. It is not medical advice, not a protocol, and not a recommendation to administer this compound to any subject. Regimens are reported as the historical record of how a cited study was conducted; findings are reported without interpretation and constitute no claim of safety or efficacy. Determining any research procedure is the sole responsibility of the qualified researcher. Products referenced on this site are supplied strictly for in-vitro laboratory and research purposes, are not for diagnostic or therapeutic use, and have not been evaluated by the FDA.